Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Conditions
Major Depressive Disorder (MDD)
Interventions
DT-101, Placebo
Drug
Lead sponsor
Draig Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Oceanside, California + 19 more
Conditions
Major Depressive Disorder
Interventions
Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo
Drug
Lead sponsor
Labopharm Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more
Conditions
Major Depressive Disorder
Interventions
Genotype-guided care
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Major Depressive Disorder
Interventions
Placebo, Escitalopram, JNJ-18038683
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

NCT07593222
Conditions
Major Depression, Healthy Participants
Interventions
Sham iTBS, TMS, D-cycloserine, Dextromethophan, Placebo
Device · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
46
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 38 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Dopamine Release in Depression

NCT02033369
Conditions
Major Depressive Disorder
Interventions
Pramipexole
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Depressive Disorder, Major
Interventions
electronic diary, Sertraline, Placebo, voice acoustics
Procedure · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Norwich, Connecticut • Aventura, Florida • Jacksonville, Florida + 7 more
Conditions
Depressive Disorder
Interventions
saredutant (SR48968), placebo, escitalopram
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years to 64 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Blinded capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Irvine, California + 21 more
Conditions
Major Depression Disorder, Depression
Interventions
DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
Drug
Lead sponsor
Deepak C. D'Souza
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Completed No phase listed Observational Accepts healthy volunteers

A Study of Pregnant and Postpartum Women With and Without Mood Disorders

NCT03615794
Conditions
Bipolar Disorder, Major Depressive Disorder, Postpartum Depression, Postpartum Psychosis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Conditions
Major Depressive Disorder
Interventions
Psychotherapy
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Dopamine on Reward Processing

NCT01253421
Conditions
Major Depressive Disorder (MDD)
Interventions
amisulpride, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Sham tDCS device, Soterix tDCS device
Device
Lead sponsor
The University of New South Wales
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Atlanta, Georgia • Towson, Maryland • Cherry Hill, New Jersey + 2 more
Conditions
Treatment Resistant Depression
Interventions
Accelerated theta-burst stimulation treatment
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Conditions
Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology, Gastrointestinal Diseases, Depressive Disorder, Depressive Episode, Adolescent Behavior, Adolescent - Emotional Problem
Interventions
SparkRx Mobile App
Device
Lead sponsor
Limbix Health, Inc.
Industry
Eligibility
13 Years to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Interventions
FOCUS (Smartphone Application), WRAP (Wellness Recovery Action Planning)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Results available

Does Dual Therapy Hasten Antidepressant Response?

NCT00519428
Conditions
Major Depressive Disorder
Interventions
escitalopram, bupropion extra long (XL), escitalopram + bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York